We have located links that may give you full text access.
"A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination".
Journal of Allergy and Clinical Immunology 2024 March 8
BACKGROUND: Systemic allergic reactions (sARs) following coronavirus disease-2019 (COVID-19) mRNA vaccines were initially reported at a higher rate than traditional vaccines.
OBJECTIVE: We aimed to evaluate the safety of revaccination in these individuals and to interrogate mechanisms underlying these reactions.
METHODS: In this randomized, double-blinded, phase 2 trial, individuals 16-69 years who previously reported a convincing sAR to their first dose of COVID-19 mRNA vaccine were randomly assigned to receive second dose of BNT162b2 (Pfizer-BioNTech; Comirnaty®) vaccine and placebo on consecutive days in a blinded, 1:1 cross-over fashion at the National Institutes of Health (NIH). Five months later, an open-label BNT162b2 booster was offered if the second dose did not result in severe sAR. None of the participants received the mRNA-1273 (Moderna; Spikevax®) vaccine during the study. The primary endpoint was recurrence of sAR following second dose and booster vaccination; exploratory endpoints included biomarker measurements.
RESULTS: Of 111 screened individuals, 18 were randomized to receive study interventions. Eight received BNT162b2 second dose followed by placebo; eight received placebo followed by BNT162b2 second dose; two withdrew before receiving any study intervention. All 16 received the booster dose. Following second dose and booster vaccination, sARs recurred in two subjects (12.5%, 95% CI 1.6-38.3). No sAR occurred after placebo. An anaphylaxis mimic, immunization stress-related response (ISRR), occurred more commonly than sARs following both vaccine and placebo and was associated with higher pre-dose anxiety scores, paresthesias, and distinct vital sign and biomarker changes.
CONCLUSION: Our findings support revaccination of individuals who report sARs to COVID-19 mRNA vaccines. Distinct clinical and laboratory features may distinguish sARs from ISRRs.
OBJECTIVE: We aimed to evaluate the safety of revaccination in these individuals and to interrogate mechanisms underlying these reactions.
METHODS: In this randomized, double-blinded, phase 2 trial, individuals 16-69 years who previously reported a convincing sAR to their first dose of COVID-19 mRNA vaccine were randomly assigned to receive second dose of BNT162b2 (Pfizer-BioNTech; Comirnaty®) vaccine and placebo on consecutive days in a blinded, 1:1 cross-over fashion at the National Institutes of Health (NIH). Five months later, an open-label BNT162b2 booster was offered if the second dose did not result in severe sAR. None of the participants received the mRNA-1273 (Moderna; Spikevax®) vaccine during the study. The primary endpoint was recurrence of sAR following second dose and booster vaccination; exploratory endpoints included biomarker measurements.
RESULTS: Of 111 screened individuals, 18 were randomized to receive study interventions. Eight received BNT162b2 second dose followed by placebo; eight received placebo followed by BNT162b2 second dose; two withdrew before receiving any study intervention. All 16 received the booster dose. Following second dose and booster vaccination, sARs recurred in two subjects (12.5%, 95% CI 1.6-38.3). No sAR occurred after placebo. An anaphylaxis mimic, immunization stress-related response (ISRR), occurred more commonly than sARs following both vaccine and placebo and was associated with higher pre-dose anxiety scores, paresthesias, and distinct vital sign and biomarker changes.
CONCLUSION: Our findings support revaccination of individuals who report sARs to COVID-19 mRNA vaccines. Distinct clinical and laboratory features may distinguish sARs from ISRRs.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app